▶ PT-141 · SUBTOPIC · DOSING LITERATURE
PT-141 Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of PT-141. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for PT-141 reports the following route(s) of administration: Subcutaneous (FDA-approved Vyleesi formulation). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of PT-141.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for PT-141 of approximately 2.7 hours (subcutaneous). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of PT-141. Refer to the original publication for full protocol detail.
- Kingsberg SA, Clayton AH, et al. (2019) reports the PT-141 protocol used in Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials, published in Obstet Gynecol. PMID 31022173. See the source for the protocol-level dose range, frequency, and duration. link
- Clayton AH, et al. (2016) reports the PT-141 protocol used in Bremelanotide for female sexual dysfunctions in premenopausal women, published in Womens Health (Lond). PMID 27193591. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What's the approved dose?
Single 1.75 mg subcutaneous injection administered at least 45 minutes before anticipated sexual activity. Per Vyleesi label.
▶ Side effects?
Most common: transient nausea (~40% incidence at the approved dose). Less common: facial flushing, headache, injection-site reactions, mild transient blood pressure increase.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · -20 °C 24 months
Reconstituted · 2-8 °C 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · FDA-approved as Vyleesi (bremelanotide) for HSDD in premenopausal women (June 2019).
WADA · Not currently listed on the WADA Prohibited List.
RELATED PAGES
▶ LAST UPDATED · 2026-05-19